ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Novartis says Entresto outperforms heart failure drug enalapril in key study
November 13, 2018Novartis presented study data at the American Heart Association's (AHA) scientific sessions showing that Entresto (sacubitril/valsartan) outperformed enalapril in patients with heart failure with reduced ejection fraction requiring hospitalisation for an -
Here’s the Chance?! A Core Patent of Novartis’ Entresto in China is Fully Declared Invalid
January 18, 2018The festive atmosphere has become increasingly strong as the Chinese New Year is approaching, and there has been good news in the pharmaceutical circle in China... -
Which is to dominate the future heart failure drug market?(2)
October 27, 2017Sales of Entresto® rising steadily upon the Class I recommendation by the European and American heart failure guideline... -
Novartis heart-failure med Entresto cuts A1c
March 21, 2017Entresto is indicated to reduce the risk of cardiovascular (CV) death and hospitalization for HF in patients with chronic HF (NYHA Class II-IV) and reduced ejection fraction
Pharma Sources Insight January 2025
